GovChime
Notice ID: 883cad98d13c4a1386c91d9184c8f1f2Combined Synopsis/Solicitation

Human primary CD34+ Hematopoietic stem and Progenitor cells

Archived on September 16, 2020. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
12:00 PM UTC−05:00
Posted
August 18, 2020
Notice type
Combined Synopsis/Solicitation
NAICS
325413: In-Vitro Diagnostic Substance Manufacturing
Agency
Department of Health and Human ServicesFOOD AND DRUG ADMINISTRATION

Notice details

Office
FDA OFFICE OF ACQ GRANT SVCS
Place of performance
Silver Spring, MD, 20993
Last updated
Apr 29, 2026

Identifiers

Solicitation number
FDA-SOL-1233197
Notice ID
883cad98d13c4a1386c91d9184c8f1f2

Description

The U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER) / Division of Cell and Gene Therapy (DCGT), Office of Cellular, Tissue and Gene Therapy requires Human primary CD34+ hematopoietic stem and progenitor cells to have assessed identity and characterization of gene and cell therapy products to perform critical path research for its mission to develop and promote technology to regulate cellular and genetic therapeutics.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:FDA-SOL-1233197
  1. Combined Synopsis
  1. Combined SynopsisCurrentAug 18, 2020

    Human primary CD34+ Hematopoietic stem and Progenitor cells

    Notice 883cad98d13c4a1386c91d9184c8f1f2 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

FDA-SOL-1233197

Archive Date

Sep 16, 2020

Office Address

Beltsville, MD, 20705